In early August, Pfizer (NYSE: PFE) announced its intent to acquire Global Blood Therapeutics (Nasdaq:GBT) for $68.50 per share, or approximately $5.4 billion. Now, however, investors are pushing back, alleging that GBT executives made incomplete and misleading statements to win shareholder approval for the prospective deal. In a complaint filed in the Southern District of…
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion
After a banner year in 2021, Pfizer (NYSE:PFE) is on a spending spree. The company plans to acquire Global Blood Therapeutics (GBT) (Nasdaq:GBT) for $68.50 per share. The total sale price of acquisition, if it moves forward, would be roughly $5.4 billion. Global Blood Therapeutics’s therapeutic focus is primarily on sickle cell disease. In March,…